STAAR Surgical Company (STAA) |
| 24.54 -0.7 (-2.77%) 10-30 16:00 |
| Open: | 25.16 |
| High: | 25.42 |
| Low: | 24.32 |
| Volume: | 535,472 |
| Market Cap: | 1,231(M) |
| PE Ratio: | 43.05 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 29.81 |
| Resistance 1: | 25.52 |
| Pivot price: | 22.77 |
| Support 1: | 22.21 |
| Support 2: | 20.16 |
| 52w High: | 35.87 |
| 52w Low: | 15.59 |
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
| EPS | 0.080 |
| Book Value | 7.290 |
| PEG Ratio | 0.76 |
| Gross Profit | 5.189 |
| Profit Margin (%) | 1.13 |
| Operating Margin (%) | 10.89 |
| Return on Assets (ttm) | 5.7 |
| Return on Equity (ttm) | 1.1 |
Thu, 29 Oct 2026
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific - citybiz
Thu, 29 Oct 2026
A former STAAR executive will return to lead its Asia-Pacific business outside China - Stock Titan
Thu, 29 Oct 2026
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific - Yahoo Finance
Wed, 28 Oct 2026
STAAR Surgical Company (STAA) Stock Forecasts - Yahoo Finance
Tue, 27 Oct 2026
STAAR Surgical to Participate in Upcoming Investor Conferences - Business Wire
Thu, 01 Oct 2026
STAAR Surgical: A Recovery Story Priced As Growth - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |